Guggenheim raised the firm’s price target on AstraZeneca (AZN) to 16,000 GBp from 15,500 GBp and keeps a Buy rating on the shares. The firm is updating its model following FY25 results and follow up presentations at several investor conferences.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca, Daiichi Sankyo announce priority review for Enhertu sBLA
- Controversial Prasad leaving FDA, NYT reports
- AstraZeneca Halts Early KRASG12D Cancer Trial, Shifting Focus in Competitive Oncology Race
- AstraZeneca CEO Receives 101,495 Shares as Long-Term Incentive Award Vests
- AstraZeneca Executives Receive Vested Deferred Share Awards